ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

(S)-シタロプラムしゅう酸塩

Escitalopram Oxalate

HCID 146571
反応を作成
印刷

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
219861-08-2
標準SMILES
CN(C)CCC[C@@]1(c2ccc(F)cc2)OCc2cc(C#N)ccc21.O=C(O)C(=O)O
InChIKey
KTGRHKOEFSJQNS-BDQAORGHSA-N
分子式
C22H23FN2O5
平均分子量
414.4 g/mol
単同位体質量
414.1591

概要

Escitalopram Oxalate is the oxalate salt of escitalopram, a pure S-enantiomer of the racemic bicyclic phthalane derivative citalopram, with antidepressant activity. As a selective serotonin reuptake inhibitor (SSRI), escitalopram blocks the reuptake of serotonin by neurons in the central nervous system (CNS), thereby potentiating CNS serotonergic activity.

名称と識別子

優先名称
Escitalopram Oxalate
IUPAC
(1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile;oxalic acid
現地名
(S)-シタロプラムしゅう酸塩
英語名
Escitalopram oxalate
分子式
C22H23FN2O5
分子量
414.43

名称と別名

Escitalopram oxalate219861-08-2DTXSID1046003Escitalopram (as oxalate)Lu 26-054-0Citalopram oxalate, (s)-5U85DBW7LONSC-758934Lu-26-054-0LU-26-054-ODTXCID9026003Escitslopram
名称をさらに表示
(S)-シタロプラムしゅう酸塩(S)-1-[3-(ジメチルアミノ)プロピル]-1-(4-フルオロフェニル)-1,3-ジヒドロイソベンゾフラン-5-カルボニトリルしゅう酸塩エスシタロプラムしゅう酸塩しゅう酸(S)-シタロプラムエスシタロプラム シュウ酸塩エスシタロプラムシュウ酸塩 (JAN)CipralexescitalopraM oxalat(S)-Citalopram-d6 Oxalate(1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile(1S)-1-[3-(Dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile EthanedioateCS-323(S)-CITALOPRAMEscitalopraM API(S)-Citalopram-d6ESCIFALOPRAMOXALATE
Escitalopram OralEscitalopram Oral SolutionRefChem:563795-Isobenzofurancarbonitrile, 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydro-,(1S)-, ethanedioate(1:1)Lexapro(S)-Citalopram Oxalate(S)-(+)Citalopram oxalateEscitalopram (oxalate)

物性

構造計算による物性補完中

極性表面積
111 Ų
水素結合供与体数
2
水素結合受容体数
8
回転可能結合数
6
重原子数
30
形式電荷
0
複雑度
537

実験および物理化学的性質

Human Drugs · 2 件

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Collision Cross Section178.8 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

物理化学的性質

融点
152 · 152-153°C
比旋光度
12.31 ° · D +12.31° (c = 1 in methanol)
貯蔵温度
2 · 2-8°C
溶解性
15 mg/mL以上 · DMSO:15mg/mL以上
外見
粉
酸解離定数(Pka)
4.19 · 4.19 (acid)
色
白から黄褐色
Merck
14 · 14,2318
BCS Class
1 · 1
安定性
吸湿性
InChI
InChI=1S/C20H21FN2O.C2H2O4/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20;3-1(4)2(5)6/h4-9,12H,3,10-11,14H2,1-2H3;(H,3,4)(H,5,6)
InChIKey
KTGRHKOEFSJQNS-UHFFFAOYSA-N
SMILES
C1(CCCN(C)C)(C2=CC=C(F)C=C2)C2=C(C=C(C#N)C=C2)CO1.C(O)(=O)C(O)=O

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Warning

H302 (14.9%): Harmful if swallowed [Warning Acute toxicity, oral]

P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 67 reports by companies from 14 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Hazard Classes and CategoriesAcute Tox. 4 (14.9%)

毒性情報

Treatment · 1 件

Establish and maintain an airway to ensure adequate ventilation and oxygenation. Gastric evacuation by lavage and use of activated charcoal should be considered. Careful observation and cardiac and vital sign monitoring are recommended, along with general symptomatic and supportive care. Due to the large volume of distribution of escitalopram, forced diuresis, dialysis, hemoperfusion, and exchange transfusion are unlikely to be of benefit. There are no specific antidotes for Escitalopram. (L1712)

Exposure RoutesThe absolute bioavailability of citalopram is about 80% relative to an intravenous dose.
Toxicity Summary · 1 件

The antidepressant, antiobsessive-compulsive, and antibulimic actions of escitalopram are presumed to be linked to its inhibition of CNS neuronal uptake of serotonin. Escitalopram blocks the reuptake of serotonin at the serotonin reuptake pump of the neuronal membrane, enhancing the actions of serotonin on 5HT<sub>1A</sub> autoreceptors. SSRIs bind with significantly less affinity to histamine, acetylcholine, and norepinephrine receptors than tricyclic antidepressant drugs.

化学と産業

薬理情報

Metabolism/Metabolites · 1 件

Mainly hepatic. Escitalopram undergoes <i>N</i>-demethylation to <i>S</i>-demethylcitalopram (S-DCT) and <i>S</i>-didemethylcitalopram (S-DDCT). CYP3A4 and CYP2C19 are the enzymes responsible for this <i>N</i>-demethylation reaction. Route of Elimination: Following oral administrations of escitalopram, the fraction of drug recovered in the urine as escitalopram and <i>S</i>-demethylcitalopram (S-DCT) is about 8% and 10%, respectively. The oral clearance of escitalopram is 600 mL/min, with approximately 7% of that due to renal clearance. Escitalopram is metabolized to S-DCT and <i>S</i>-didemethylcitalopram (S-DDCT). Half Life: 27-32 hours

FDA Pharmacological Classification · 6 件

ESCITALOPRAM ORAL

Serotonin Reuptake Inhibitor [EPC]; Serotonin Uptake Inhibitors [MoA]

ESCITALOPRAM OXALATE

Serotonin Uptake Inhibitors [MoA]; Serotonin Reuptake Inhibitor [EPC]

ESCITSLOPRAM

Serotonin Reuptake Inhibitor [EPC]; Serotonin Uptake Inhibitors [MoA]

MeSH Pharmacological ClassificationCompounds that specifically inhibit the reuptake of serotonin in the brain.

用途と製造

UsesLabeled indications include major depressive disorder (MDD) and generalized anxiety disorder (GAD). Unlabeled indications include treatment of mild dementia-associated agitation in nonpsychotic patients.
応用分野 · 3 件

説明Escitalopram was launched as Cipralex in Switzerland, Sweden and UK for the treatment of depression and panic disorder. It is the S-enantiomer version of the selective serotonin reuptake inhibitor (SSRI) citalopram approved in 1989. It can be obtained from 5cyanophthalide by successive reactions with 4-fluorophenyl magnesium bromide and 3-(dimethylamino)propyl magnesium chloride. The resulting racemic diol can be resolved by several routes such as crystallization with a chiral acid. Finally, a two step cyclisation procedure affords escitalopram. Escitalopram is twice as effective as the racemate and over 100 fold more potent than the R-enantiomer in inhibiting the 5HT reuptake in vivo in rat brain synaptosomes. Moreover, it exhibits higher selectivity for the human serotonin transporter relative to the noradrenaline or dopamine transporters than any other currently available SSRl’s. In the mouse forced swim test, the duration of immobility (which reflects antidepressant activity) for escitalopram was comparable to citalopram and greater than (R)-citalopram. Clinical trials in patients with panic disorders or depression have shown that escitalopram has a clinically relevant and significant effect. Additionally, it has a faster onset of antidepressant action than citalopram. Escitalopram has linear pharmacokinetics, with a long half-life (27-32 h). It is extensively metabolized in the liver via cytochromes P450 to S(+)-desmethyl and S(+)-didesmethyl citalopram. However, it has been shown to be a weak or negligible inhibitor of CYP450 drugmetabolizing enzymes in vitro. Escitalopram is well tolerated with nausea being the most common side effect.

関連反応

18 件
反応記録を作成
HRID 77255 の反応式
HRID 77255反応物として
HRID 227687 の反応式
HRID 227687生成物として
HRID 1174049 の反応式
HRID 1174049生成物として
HRID 1669960 の反応式
HRID 1669960生成物として
HRID 1669961 の反応式
HRID 1669961生成物として
HRID 1669962 の反応式
HRID 1669962生成物として
HRID 1669963 の反応式
HRID 1669963生成物として
HRID 1669965 の反応式
HRID 1669965生成物として
前へ1 / 3 ページ

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

データベース識別子

CAS
219861-08-2
PubChem CID
146571
DTXSID
DTXSID1046003
ChEMBL
CHEMBL1200322
UNII
5U85DBW7LO
EC Number
620-544-8
CAS データベース
219861 · 219861-08-2(CAS DataBase Reference)

化学的性質

化学的特性White Solid

Signs and SymptomsSigns of overdose include convulsions, coma, dizziness, hypotension, insomnia, nausea, vomiting, sinus tachycardia, somnolence, and ECG changes (including QT prolongation).
Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 6 件

Drug Induced Liver Injury Rank (DILIrank 2.0)

Escitalopram oxalate

vLess-DILI-concern

7

Adverse reactions

DOI:10.1016/j.drudis.2016.02.015

安全データ

wgk
3
rtecs
NP6333500
hs_code
29322090
risk_code
36/37/38
hazard_code
Xi
safety_code
26-36
毒劇物取締法
劇物
Hazard Classifications
Acute Tox. 4 DermalAcute Tox. 4 Oral
ストレージクラス
11 - Combustible Solids

使用Escitalopram oxalate may be used as a pharmaceutical primary standard for the quantification of the analyte in pharmaceutical formulations using analytical techniques.

一般的な説明Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards. Escitalopram Oxalate, a highly selective serotonin re-uptake inhibitor antidepressant, is a pure S-enantiomer of the racemic, bicyclic pthalates derivatives of citalopram. It is mainly developed for the treatment of depression and anxiety disorders.

上流・下流製品情報

上流原料

4-[(S)-1-ヒドロキシ-1-(4-フルオロフェニル)-4-(ジメチルアミノ)ブチル]-3-(ヒドロキシメチル)ベンゾニトリルエスシタロプラムシュウ酸